GeneDx Holdings annual free cash flow
2019
2020
2021
2022
2023
2024
2025
GeneDx Holdings Free Cash Flow (FCF) History (WGS)
GeneDx Holdings reported $14.3M in free cash flow for fiscal 2025, an increase of $48.2M from the previous fiscal year, with a free cash flow margin of 3.34%.
View full GeneDx Holdings company overviewGeneDx Holdings free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | $14.3M | $48.2M | — | +3.34% |
| 2024 | 2024-12-31 | −$34.0M | $151.4M | — | −11.13% |
| 2023 | 2023-12-31 | −$185.4M | $140.9M | — | −91.52% |
| 2022 | 2022-12-31 | −$326.3M | −$126.5M | — | −139.04% |
| 2021 | 2021-12-31 | −$199.8M | −$82.6M | — | −94.17% |
| 2020 | 2020-12-31 | −$117.2M | −$86.6M | — | −65.37% |
| 2019 | 2019-12-31 | −$30.7M | — | — | −15.62% |
GeneDx Holdings quarterly free cash flow
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$39.1M | −$47.1M | — | −34.16% |
| Q1 2026 | 2026-03-31 | −$38.9M | −$42.9M | — | −38.00% |
| Q4 2025 | 2025-12-31 | −$7.4M | −$1.2M | — | −6.15% |
| Q3 2025 | 2025-09-30 | $9.6M | $14.6M | — | +8.22% |
| Q2 2025 | 2025-06-30 | $8.1M | $13.9M | — | +7.84% |
| Q1 2025 | 2025-03-31 | $4.1M | $20.9M | — | +4.65% |
| Q4 2024 | 2024-12-31 | −$6.2M | $26.0M | — | −6.52% |
| Q3 2024 | 2024-09-30 | −$5.0M | $36.3M | — | −6.56% |
| Q2 2024 | 2024-06-30 | −$5.9M | $50.4M | — | −8.31% |
| Q1 2024 | 2024-03-31 | −$16.9M | $38.7M | — | −27.00% |
| Q4 2023 | 2023-12-31 | −$32.2M | $34.6M | — | −56.14% |
| Q3 2023 | 2023-09-30 | −$41.3M | $49.3M | — | −77.56% |
| Q2 2023 | 2023-06-30 | −$56.3M | $29.8M | — | −115.52% |
| Q1 2023 | 2023-03-31 | −$55.6M | $27.3M | — | −128.79% |
| Q4 2022 | 2022-12-31 | −$66.8M | −$9.8M | — | −108.92% |
| Q3 2022 | 2022-09-30 | −$90.6M | −$18.6M | — | −108.85% |
| Q2 2022 | 2022-06-30 | −$86.0M | −$59.5M | — | −237.81% |
| Q1 2022 | 2022-03-31 | −$82.9M | −$38.6M | — | −153.63% |
| Q4 2021 | 2021-12-31 | −$57.0M | — | — | −98.69% |
| Q3 2021 | 2021-09-30 | −$72.0M | — | — | −166.67% |
| Q2 2021 | 2021-06-30 | −$26.5M | — | — | −56.46% |
| Q1 2021 | 2021-03-31 | −$44.3M | — | — | −68.98% |
GeneDx Holdings free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from −$117.2M to $14.3M, a net increase of $131.5M. GeneDx Holdings's latest reported quarter, Q2 2026, generated −$39.1M in free cash flow, a decrease of $47.1M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review GeneDx Holdings filings at SEC.gov ↗